Evidence map›Paper›PMID 35994093›Full record

ReviewJournal of gastroenterology2022

Evidence-based clinical practice guidelines for chronic pancreatitis 2021.

Kyoko Shimizu, Tetsuhide Ito, Atsushi Irisawa, Takao Ohtsuka, Hirotaka Ohara, Atsushi Kanno, Mitsuhiro Kida, Junichi Sakagami, Naohiro Sata, Yoshifumi Takeyama and 8 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Idiopathic chronic pancreatitis: clinical highlights.Therapeutic advances in gastroenterology · 2026
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Kyoko ShimizuGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan. shimizu.kyoko@twmu.ac.jp.ORCID http://orcid.org/0000-0003-1221-0315
Tetsuhide ItoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Atsushi IrisawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Takao OhtsukaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Hirotaka OharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Atsushi KannoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Mitsuhiro KidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Junichi SakagamiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Naohiro SataGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Yoshifumi TakeyamaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Junko TaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Morihisa HirotaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Nao FujimoriGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Atsushi MasamuneGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Satoshi MochidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Nobuyuki EnomotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tooru ShimosegawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazuhiko KoikeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Chronic Pancreatitis'', The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
The Japanese Society of Gastroenterological Surgery · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic pancreatitis (CP) is defined according to the recently proposed mechanistic definition as a pathological fibro-inflammatory syndrome of the pancreas in individuals with genetic, environmental, and/or other risk factors who develop persistent pathological responses to parenchymal injury or stress.

methodsThe clinical practice guidelines for CP in Japan were revised in 2021 based on the 2019 Japanese clinical diagnostic criteria for CP, which incorporate the concept of a pathogenic fibro-inflammatory syndrome in the pancreas. In this third edition, clinical questions are reclassified into clinical questions, background questions, and future research questions.

resultsBased on analysis of newly accumulated evidence, the strength of evidence and recommendations for each clinical question is described in terms of treatment selection, lifestyle guidance, pain control, treatment of exocrine and endocrine insufficiency, and treatment of complications. A flowchart outlining indications, treatment selection, and policies for cases in which treatment is ineffective is provided. For pain control, pharmacological treatment and the indications and timing for endoscopic and surgical treatment have been updated in the revised edition.

conclusionsThese updated guidelines provide clinicians with useful information to assist in the diagnosis and treatment of CP.

Indexed as

Pancreatitis, ChronicEndoscopyHumansPainPancreasRisk Factors2019 CP clinical diagnostic criteriaDiagnosisEarly chronic pancreatitisEndoscopic treatmentMechanistic definitionPancreatic enzyme replacement therapyPancreatic exocrine insufficiencyPancreatogenic diabetesPathogenic fibro-inflammatory syndromePrognosisStagingSurgical treatment

Identifiers

PMID35994093
PMCPMC9522716
OpenAlexW4292648307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.